6728results about "Extracellular fluid disorder" patented technology

The present application relates to animal bifidobacterium lactis Ca360 and its application. The present application also provides the application of animal bifidobacterium lactis in promoting the absorption and transport of minerals, improving osteoporosis, iron deficiency anemia and zinc deficiency. The animal bifidobacterium lactis of the present application can promote the absorption and transport of minerals, improve osteoporosis, iron deficiency anemia and zinc deficiency.

Aspects of the disclosure provides composition and methods for treating a subject having a blood loss condition, the method comprising administering to the subject a hemojuvelin (HIV) antagonist (e.g., anti-HJV antibody).

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The invention provides a compound of a GLP-1R agonist or modulator with a structure as shown in a formula (I).

Relates to a multispecific antibody or antigen binding fragment specifically binding to LIGHT and GM-CSFR alpha, a composition containing the antibody or antigen binding fragment specifically binding to LIGHT and the antibody or antigen binding fragment specifically binding to GM-CSFR alpha, a pharmaceutical composition containing the multispecific antibody or composition, and a preparation method and application thereof. Including methods of using the same to prevent and treat inflammatory, respiratory or autoimmune diseases.

The invention relates to a monoclonal antibody with anticoagulant activity and application thereof, the antibody or fragment comprises a light chain variable region and a heavy chain variable region, and the amino acid sequence of the light chain variable region of the antibody or fragment is as shown in SEQ ID NO: 1; the amino acid sequence of the variable region of the heavy chain is as shown in SEQ ID NO: 3. The monoclonal antibody disclosed by the invention has the effect of inhibiting the activity of a co-coagulation pathway in a coagulation cascade reaction, and can be applied to prevention and treatment of thrombotic diseases.

The invention discloses an antibody-modified lipid nanoparticle, a preparation method thereof and application of the antibody-modified lipid nanoparticle as a targeting carrier. The invention provides lipid nanoparticles coupled with an antibody and loaded with nucleic acid. The lipid nanoparticles are characterized in that raw materials of the lipid nanoparticles consist of ionizable lipid, phospholipid, steroidal lipid, PEG lipid and PEG-Mal lipid, the PEG lipid is C16-PEG2k, and the PEG-Mal lipid is C16-PEG2k-Mal, and the PEG-Mal lipid is C16-PEG2k-Mal. The method aims at the key scientific problems of low delivery efficiency, insufficient targeting and the like in the field of in-vivo hematopoietic stem / progenitor cell gene therapy at present. The invention develops a lipid nanoparticle delivery system based on antibody modification, provides a modular antibody targeted delivery platform with high universality, and shows huge clinical transformation potential.

The invention discloses an oral care composition containing ampelopsis japonica polysaccharide and application of the oral care composition in inhibiting gingival bleeding. The oral care composition comprises ampelopsis japonica polysaccharide and an orally acceptable carrier, wherein the pH (Potential of Hydrogen) range of the oral care composition is 5.9 to 7.7. The invention also discloses an application of the ampelopsis japonica polysaccharide in the oral care composition for inhibiting gingival bleeding. The invention discloses application of silicon dioxide with a high oil absorption value in an oral care composition for improving the gingival bleeding inhibiting effect of ampelopsis japonica polysaccharide. The combination of the high-oil-absorption-value silicon dioxide and the low-oil-absorption-value silicon dioxide is applied to the oral care composition for improving the gingival bleeding inhibiting effect of the ampelopsis japonica polysaccharide; the invention further discloses application of sorbitol in the oral care composition for improving the effect of inhibiting gingival bleeding by the ampelopsis japonica polysaccharide. The oral care composition has a hemostatic effect and can effectively solve the problem of gingival bleeding.

The invention relates to ultra-small prussian blue nano-particles (T-USPB-C) carrying tirofian, a preparation method of the nano-particles and application of the nano-particles in preparation of drugs for reducing MVO and MIRI. According to the preparation method, the T-USPB-C is prepared by three steps. The T-USPB-C provided by the invention can carry tirofiban, and has catalase and superoxide dismutase simulated nano-enzyme activity. Moreover, the size of the nano-scale drug is required to reach a nano-scale size, and the drug can be efficiently cleared through kidney excretion, so that the potential long-term toxicity problem is minimized. The ultra-small prussian blue nanoparticle carrying the tirofian has an excellent active oxygen scavenging capability. Microvascular perfusion can be rapidly improved through the antithrombotic effect, then the protection effect is continuously achieved through the anti-oxidation and anti-inflammatory mechanism, and microvascular injury and MIRI are effectively prevented.

The invention provides a method for efficiently extracting tea polyphenol and tea polysaccharide and application, and belongs to the technical field of plant extraction.The extraction method comprises the following steps that tea leaves are pre-cooled and rolled and cut to obtain pretreated tea leaves, then the pretreated tea leaves are added into water to be mixed, biological enzyme is added for ultrasonic enzymolysis, filtering is conducted, and filtrate and tea residues are obtained; adding tea residues into water, mixing, adding an auxiliary agent, and carrying out low-temperature plasma treatment and filtration to obtain a filtrate; combining the filtrates, concentrating, precipitating, centrifuging, and collecting precipitate and supernate; washing and drying the precipitate to obtain a tea polysaccharide extract; and concentrating, extracting, adsorbing, eluting, re-concentrating and drying the supernate to obtain the tea polyphenol extract. The extraction method disclosed by the invention can be used for efficiently extracting the tea polyphenol and the tea polysaccharide in the tea leaves, the product yield and purity are high, and the tea polyphenol and the tea polysaccharide can be used for preparing health-care products for relieving diabetes and polyuria.

The present invention provides a pharmaceutical composition, the composition comprises a therapeutically effective amount of bumetanib, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutic adjuvants, and the specific antioxidants are selected from one or more of fat-soluble vitamin C derivatives or phenolic antioxidants. In addition, the invention also discloses a method for improving the stability of the bumetanib pharmaceutical composition. According to the technical scheme, the problems of generation and growth of N-nitroso bumetanib and other related substances in the production and storage process of the bumetanib solid preparation are effectively solved, and the drug stability and the medication safety are remarkably improved.

The present disclosure relates to compositions and methods of increasing levels of fetal hemoglobin (HbF) in cells. The present disclosure further relates to methods for treating patients suffering from blood cell diseases, including those associated with reduced amounts of functional adult hemoglobin (HbA), such as sickle cell disease and β-thalassemias

Provided herein are pharmaceutical compositions comprising carotenoids, including liposomes that encapsulate carotenoids including ionizable carotenoids such as trans-crocetin. The provided compositions have uses in treating diseases, disorders and conditions associated with, but not limited to, infection, endotoxemia, inflammation, sepsis, ischemia, hypoxia, shock, stroke, lung injury, wound healing, traumatic injury, reperfusion injury, cardiovascular disease, kidney disease, liver disease, inflammatory disease, metabolic disease, pulmonary disorders, blood related disorders and hyperproliferative diseases such as cancer. Methods of making, delivering, and using the pharmaceutical compositions are also provided.

The invention provides an extraction method of hirudin, an oral preparation containing the hirudin and a preparation method of the oral preparation, and belongs to the technical field of leech processing and traditional Chinese medicine. The hirudin extraction method comprises the following steps: S1, soaking fresh leeches in a freeze-drying protective agent, taking out the leeches, wiping the surfaces of the leeches, pre-freezing the leeches at the temperature of 40 DEG C below zero to 50 DEG C below zero for 1-2 hours, and freeze-drying the leeches at the temperature of 20 DEG C below zero to 30 DEG C below zero for 4-6 hours to obtain freeze-dried leeches; s2, crushing the freeze-dried leeches, adding the crushed leeches into water, adding enzyme and lecithin, performing enzymolysis for 4-6 hours under the conditions that the temperature is 35-40 DEG C and the pH value is 7.5-8.5, and cooling to room temperature to obtain an enzymolysis product; s3, sterilization, ultrafiltration and drying are conducted, and hirudin is obtained. The hirudin extracted by the method is high in activity and high in recovery rate.

The present invention relates to a nucleic acid molecule for inhibiting FXI gene expression through RNAi, and more particularly, to a nucleic acid molecule for inhibiting FXI gene expression through RNAi, the nucleic acid molecule comprises a sense sequence and an antisense sequence which are complementary to each other or is composed of a sense sequence and an antisense sequence which are complementary to each other, and the FXI inhibition rate of the nucleic acid molecule is significantly superior to that of other small nucleic acid molecules for inhibiting FXI expression through RNAi.

To provide a new composition for increasing expression of the Klotho gene and an application thereof.SOLUTION: The present disclosure provides, in one aspect, the following invention: a composition for enhancing expression of the human Klotho / KL gene, the composition comprising at least a portion of a protein belonging to the TNF superfamily or a nucleic acid encoding at least a portion of the protein.SELECTED DRAWING: None

To provide an oral composition for effectively activating plasmacytoid dendritic cells (pDCs).SOLUTION: An oral composition for activating plasmacytoid dendritic cells (pDCs), comprising Lacticaseibacillus rhamnosus CRL1505, wherein the composition is preferably intended for immune activation. The oral composition for activating pDCs is considered to: regulate both innate immunity and acquired immunity; act on an overall immune function, maintain a normal immune function, and maintain good physical conditions. The present invention also provides an oral composition for immune activation characterised in that it comprises Lacticaseibacillus rhamnosus CRL1505, wherein the immune activation is intended for symptoms such as nasal congestion.SELECTED DRAWING: Figure 1

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to application of bifidobacterium longum subsp. Infantis Y46 in the anti-aging aspect. The bifidobacterium longum subsp. Infantis Y46 is obtained from excrement of infants. Animal experiments prove that living cell thalli (Y46) and thermally inactivated cell thalli (HKY46) obtained by culturing the bifidobacterium longum subsp. Infantis Y46 by using an MRS liquid culture medium containing L-cysteine hydrochloride (0.05%, v / v) can significantly reduce accumulation of lipofuscin in a host, and prolong the healthy life and life of the host. Therefore, the bifidobacterium longum subsp. Infantis Y46 is a promising probiotic and a promising metagen with an anti-aging function.

The invention belongs to the technical field of traditional Chinese medicine preparation, and particularly relates to a peach kernel and safflower four-ingredient decoction compound preparation and a preparation method and a quality control method thereof. The invention provides a preparation method of a peach kernel and safflower four-component decoction compound preparation by screening and optimizing an enrichment method of volatile oil in extraction, concentration, inclusion and drying processes on the basis of an ancient water decoction process. According to the peach kernel and safflower four-drug decoction compound preparation prepared by the invention, the quality consistency with a reference sample is realized, including the consistency of each content index in the compound preparation with the reference sample and the consistency of a fingerprint spectrum with the reference sample; especially, characteristic peaks of volatile components-ligustilide, senkyunolide I and senkyunolide A are presented in the fingerprint spectrum, and the consistency of the content of the volatile oil is determined. Moreover, the quality control method provided by the invention is expected to be used for quality control of industrial large-scale production of a classic famous prescription, namely the peach kernel and safflower four-ingredient decoction compound preparation, and has a good application prospect.

The invention discloses a cationic lipid compound, a lipid carrier containing the same and application, and belongs to the technical field of gene therapy. The cationic lipid compound disclosed by the invention has a structure as shown in a formula I, or an isomer, a pharmaceutically acceptable salt and a prodrug thereof. The lipid nanoparticles have the advantages of stable nanostructure, uniform size distribution, good biological biocompatibility, high in-vivo and in-vitro mRNA delivery efficiency, selective organ targeting and the like. The cationic lipid reaction operation is simple, the raw materials are cheap and easy to obtain, and the cationic lipid has high safety, is beneficial to industrial production and quality control, and has a good application prospect.

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.

The invention provides application of active decapeptide in preparation of a medicine for preventing or treating cerebral apoplexy, and belongs to the technical field of biological medicine, the active decapeptide with the amino acid sequence as shown in SEQ ID NO.1 is applied to prevention or treatment of cerebral apoplexy for the first time, the active decapeptide can effectively inhibit formation of cerebral thrombosis of zebra fish with ischemic cerebral apoplexy, and the active decapeptide can be used for preventing or treating cerebral apoplexy. The brain blood flow supply is recovered; meanwhile, the active decapeptide can significantly reduce the hemorrhagic area and hemorrhagic rate of the zebra fish brain with hemorrhagic stroke, repair brain vascular injury and inhibit the occurrence and development of hemorrhagic stroke. In addition, the active decapeptide has small toxic and side effects, and is of great significance for improving the clinical curative effect of cerebral apoplexy and reducing the medication risk when being used for research and development of novel drugs for resisting cerebral apoplexy.

The invention discloses a water-soluble bornyl ester compound and application thereof, the structure of the water-soluble bornyl ester compound is as shown in general formula I, R is acetic acid 2-oxoethyl ester of organic heterocyclic ring, amino acid 2-oxoethyl ester, glycolate of amino acid, acetal of monodisperse polyethylene glycol chain, carbonate, ester or glycosyl; the compound is good in water solubility, the problems that borneol is difficult to dissolve in water and difficult to prepare can be well solved, and in an inflammatory depression animal model, the bornyl ester compound shows good anti-inflammatory, anti-depression and cerebral apoplexy treatment effects and has great application prospects.

The invention relates to the field of biological medicine, and provides an application of a dihydroorotate dehydrogenase inhibitor in preparation of megakaryocytes, and the dihydroorotate dehydrogenase inhibitor is a compound shown as a formula I, a formula II or a formula III, or a pharmaceutically acceptable salt of the compound. According to the technical scheme, the dihydroorotate dehydrogenase inhibitor can promote hematopoietic stem / progenitor cells to differentiate into megakaryocytes and platelets, the platelet generation amount is increased by about 2 times, and a promising strategy is provided for in-vivo and in-vitro megakaryocyte and platelet generation.

The disclosure features systems and methods for correcting a mutation in the human beta-globin (HBB) gene in a cell or population of cells. The disclosure also features methods of increasing repair of a DNA double stranded break (DSB) in an HBB gene by the homology-directed repair (HDR) pathway. The disclosure also features compositions for use in the methods.

Disclosed are compounds, pharmaceutical compositions and uses thereof as complement factor D inhibitors, specifically a compound represented by formula (I), its tautomers, its stereoisomers, its prodrugs, or any one of the foregoing pharmaceutically acceptable salts, or any one of the foregoing solvates, wherein the compound has excellent inhibitory activity against complement factor D and has excellent pharmacokinetic and pharmacodynamic activity. JPEG2024533782000131.jpg47170